209 related articles for article (PubMed ID: 35269477)
1. RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with
Sidorova OA; Sayed S; Paszkowski-Rogacz M; Seifert M; Camgöz A; Roeder I; Bornhäuser M; Thiede C; Buchholz F
Cells; 2022 Mar; 11(5):. PubMed ID: 35269477
[No Abstract] [Full Text] [Related]
2. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
3. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
4. Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.
Park SH; Choi JC; Kim SY; Yi J; Oh SH; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Biomed Res Int; 2015; 2015():723682. PubMed ID: 25650308
[TBL] [Abstract][Full Text] [Related]
5. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
6. Identification of Cell Type-Specific Effects of
Bae SG; Kim HJ; Kim MY; Kim DDH; Shin SI; Ahn JS; Park J
Mol Cells; 2023 Oct; 46(10):611-626. PubMed ID: 37853686
[TBL] [Abstract][Full Text] [Related]
7. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming.
Yang X; Wang X; Yang Y; Li Z; Chen Y; Shang S; Wang Y
J Transl Med; 2023 Jul; 21(1):481. PubMed ID: 37464424
[TBL] [Abstract][Full Text] [Related]
8. Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.
Yuan XQ; Chen P; Du YX; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Zeng WJ; Chen XP
J Transl Med; 2019 Jul; 17(1):220. PubMed ID: 31291961
[TBL] [Abstract][Full Text] [Related]
9. DNMT3A mutations in Chinese childhood acute myeloid leukemia.
Li W; Cui L; Gao C; Liu S; Zhao X; Zhang R; Zheng H; Wu M; Li Z
Medicine (Baltimore); 2017 Aug; 96(31):e7620. PubMed ID: 28767575
[TBL] [Abstract][Full Text] [Related]
10. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
[TBL] [Abstract][Full Text] [Related]
11. The methyltransferase domain of DNMT1 is an essential domain in acute myeloid leukemia independent of DNMT3A mutation.
Bhogal B; Weir BA; Crescenzo R; Marien A; Kwon MC; Philippar U; Cowley GS
Commun Biol; 2022 Nov; 5(1):1174. PubMed ID: 36329185
[TBL] [Abstract][Full Text] [Related]
12. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
[TBL] [Abstract][Full Text] [Related]
13. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
[TBL] [Abstract][Full Text] [Related]
14. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
PLoS One; 2011; 6(10):e26906. PubMed ID: 22066015
[TBL] [Abstract][Full Text] [Related]
15. miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.
Gamlen HA; Romer-Seibert JS; Lawler ME; Versace AM; Goetz ML; Feng Y; Guryanova OA; Palmisiano N; Meyer SE
Clin Cancer Res; 2022 Oct; 28(20):4574-4586. PubMed ID: 35943291
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia with DNMT3A mutations.
Li Y; Zhu B
Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
[TBL] [Abstract][Full Text] [Related]
17. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics Analysis Identifies Key Genes and Pathways in Acute Myeloid Leukemia Associated with DNMT3A Mutation.
Chen S; Chen Y; Lu J; Yuan D; He L; Tan H; Xu L
Biomed Res Int; 2020; 2020():9321630. PubMed ID: 33299888
[TBL] [Abstract][Full Text] [Related]
19. Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells.
Wang Q; Liu Y; Wang H; Jiang P; Qian W; You M; Han Y; Zeng X; Li J; Lu H; Jiang L; Zhu M; Li S; Huang K; Tang M; Wang X; Yan L; Xiong Z; Shi X; Bai G; Liu H; Li Y; Zhao Y; Chen C; Qian P
Nat Commun; 2022 Sep; 13(1):5657. PubMed ID: 36163326
[TBL] [Abstract][Full Text] [Related]
20. Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.
Que Y; Li H; Lin L; Zhu X; Xiao M; Wang Y; Zhu L; Li D
Front Immunol; 2021; 12():653030. PubMed ID: 34093541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]